Coronary Dysregulation Associated with Obesity

与肥胖相关的冠状动脉失调

• 批准号: 8397586
• 负责人: Christine L OLTMAN
• 金额: --
• 依托单位: IOWA CITY VA MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-07-01 至 2014-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8397586
• 关键词: Acetylcholine; Adenosine; Adenylate Cyclase; American Heart Association; Arteries; Attenuated; Blood Vessels; C-Type Natriuretic Peptide; Calcitonin Gene-Related Peptide; Calcitonin-Gene Related Peptide Receptor; Cardiovascular Diseases; Cardiovascular system; Caring; Complex; Coronary; Coronary Circulation; Coronary artery; Coronary heart disease; Cyclic AMP-Dependent Protein Kinases; Data; Development; Diabetes Mellitus; Diet; Dilator; Disease; Disease model; Epidemic; Evaluation; Fatty acid glycerol esters; Functional disorder; General Population; Goals; Health Care Costs; Healthcare; Heart Diseases; Hyperglycemia; Hypertension; Incidence; Individual; Innovative Therapy; Kidney Diseases; Lead; Link; Mediating; Medical; Mesenteric Arteries; Metabolic; Neprilysin; Nerve; Nerve Endings; Non-Insulin-Dependent Diabetes Mellitus; Obesity; Overweight; Pathology; Patients; Peptides; Peripheral Nervous System; Physiological; Population; Potassium Channel; Prevalence; Property; Rattus; Receptor Activation; Relaxation; Renal Circulation; Research; Resistance; Risk; Risk Factors; Role; Second Messenger Systems; Signal Pathway; Signal Transduction; Stroke; Substance P; System; Testing; United States Department of Veterans Affairs; Vascular Diseases; Vascular Smooth Muscle; Vasodilation; Vasodilator Agents; Work; afferent nerve; diabetic rat; disorder risk; feeding; hypercholesterolemia; improved; patient population; prevent; public health relevance; receptor; renal artery; response; second messenger; standard of care; therapeutic target; therapy development; vasoactive agent

DESCRIPTION (provided by applicant): Diabetes and obesity has reached epidemic levels in the patient population cared for by the Veterans Administration Medical System as well as in the general population. Obesity increases the risk for hypertension, stroke, hypercholesterolemia, heart disease, and type II diabetes. A prelude to cardiovascular disease in obesity is development of vascular dysfunction. However, the pathology linking obesity to vascular complications is not well known. In order to prevent complications associated with cardiovascular dysfunction in diabetes and obesity, it is important to improve our understanding of underlying mechanisms. Calcitonin gene-related peptide (CGRP) is a very potent physiological microvascular dilator. CGRP is released from nerve endings directly onto vascular smooth muscle to induce vasodilation. We have found that CGRP mediated dilation is attenuated in coronary arteries from high fat fed rats and in renal arteries from diabetic rats. The mechanisms involved in altered CGRP responses are not known. We believe that improving our understanding of the role of this peptide on vascular function both normal and disease models could lead to innovative therapies for vascular disease in patient populations with type 2 diabetes and obesity. The hypothesis to be tested is that abnormal vascular responses to CGRP associated with type 2 diabetes and obesity are due to decreased CGRP content in sensory nerves innervating the vasculature and alterations in degradation of CGRP, expression of CGRP receptor components and/or intracellular signaling mechanisms activated by CGRP. Our specific objectives include: 1. Determine the effect of diet induced obesity with and without type 2 diabetes on CGRP levels in the vasculature and CGRP vascular reactivity. 2. Determine mechanisms involved in vascular dysfunction associated with type 2 diabetes and obesity, including a) degradation of CGRP due to changes in expression and/or activity of NEP b) altered expression of CGRP receptor components c) alterations in activation of downstream signaling pathways following CGRP receptor activation, such as adenylate cyclase, PKA, or K+ channels. The proposed studies will use obesity resistant (OR) and obesity prone (OP) rats with and without hyperglycemia. OR rats will allow evaluation of diet on vascular reactivity. We will examine vascular reactivity in coronary, mesenteric and renal arteries. Metabolic parameters and expression of CGRP receptor components and NEP will also be determined. There is a pressing need to identify mechanisms of vascular dysfunction attributed to diabetes and obesity and to develop therapies that can prevent or reverse adverse cardiovascular consequences. With the global increase in type II diabetes and onset of obesity increasing in younger populations, the burden to deliver health care to these individuals will continue to increase.

描述（由申请人提供）： 糖尿病和肥胖症在退伍军人管理局医疗系统照顾的患者群体以及普通人群中已经达到流行病的水平。肥胖会增加高血压、中风、高胆固醇血症、心脏病和II型糖尿病的风险。肥胖者心血管疾病的前奏是血管功能障碍的发展。然而，将肥胖与血管并发症联系起来的病理学尚不清楚。为了预防与糖尿病和肥胖症心血管功能障碍相关的并发症，重要的是提高我们对潜在机制的理解。 降钙素基因相关肽（CGRP）是一种非常有效的生理性微血管扩张剂。CGRP从神经末梢直接释放到血管平滑肌上以诱导血管舒张。我们已经发现，CGRP介导的扩张在高脂肪喂养大鼠的冠状动脉和糖尿病大鼠的肾动脉中减弱。CGRP反应改变的机制尚不清楚。我们相信，提高我们对这种肽对正常和疾病模型血管功能的作用的理解，可能会导致2型糖尿病和肥胖患者人群血管疾病的创新疗法。 待检验的假设是，与2型糖尿病和肥胖症相关的对CGRP的异常血管反应是由于神经支配脉管系统的感觉神经中CGRP含量降低以及CGRP降解、CGRP受体组分表达和/或由CGRP激活的细胞内信号传导机制的改变。我们的具体目标包括：1.确定饮食诱导的肥胖伴或不伴2型糖尿病对血管系统中CGRP水平和CGRP血管反应性的影响。 2.确定与2型糖尿病和肥胖相关的血管功能障碍的机制，包括a）由于NEP表达和/或活性变化导致的CGRP降解B）CGRP受体组分的表达改变c）CGRP受体激活后下游信号通路（如腺苷酸环化酶、PKA或K+通道）激活的改变。 拟定的研究将使用伴有和不伴有高血糖症的肥胖抵抗（OR）和肥胖倾向（OP）大鼠。OR大鼠将允许评价饮食对血管反应性的影响。我们将检查冠状动脉、肠系膜动脉和肾动脉的血管反应性。还将测定代谢参数和CGRP受体组分和NEP的表达。 目前迫切需要确定糖尿病和肥胖导致的血管功能障碍的机制，并开发可以预防或逆转不良心血管后果的治疗方法。随着全球II型糖尿病的增加和年轻人群中肥胖症的增加，为这些人提供医疗保健的负担将继续增加。